| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
140,990,000 |
| Market
Cap: |
73.88(M) |
| Last
Volume: |
2,041,307 |
Avg
Vol: |
1,748,484 |
| 52
Week Range: |
$0.2971 - $1.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sangamo BioSciences is a clinical-stage genomic medicine company focused on translating science into medicines. Co.'s clinical-stage product candidates are: Isaralgagene civaparvovec (ST-920), which is Co.'s wholly-owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, which is Co.'s zinc finger nuclease gene-edited cell therapy product candidate for the treatment of sickle cell disease; TX200 for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and Giroctocogene fitelparvovec (SB-525), which is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
6,000,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$3,000,000 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Meyers James R |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
99,600 |
|
- |
|
| Beers Courtney |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
82,650 |
|
- |
|
| Markels John |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
96,384 |
|
- |
|
| Carey Robert |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
99,600 |
|
- |
|
| Horn Margaret A |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
82,650 |
|
- |
|
| Hillan Kenneth |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
99,600 |
|
- |
|
| Smith Karen L. |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
102,100 |
|
- |
|
| Parker H Stewart |
|
– • – |
2025-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
112,600 |
|
- |
|
| Duraibabu Prathyusha |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2025-05-24 |
4 |
D |
$0.47 |
$848 |
D/D |
(1,792) |
778,145 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-CHIEF DEVELOPMENT OFFICER |
• – – |
2025-05-24 |
4 |
D |
$0.47 |
$848 |
D/D |
(1,792) |
799,747 |
|
- |
|
| Macrae Sandy |
PRESIDENT, CEO AND DIRECTOR |
• • – |
2025-05-24 |
4 |
D |
$0.47 |
$3,544 |
D/D |
(7,488) |
2,318,410 |
|
- |
|
| Willoughby Scott B. |
SVP, CHIEF LEGAL OFFICER, SECY |
• – – |
2025-05-24 |
4 |
D |
$0.47 |
$678 |
D/D |
(1,433) |
781,543 |
|
- |
|
| Davis Gregory D |
Head of Research & Technology |
• – – |
2025-05-24 |
4 |
D |
$0.47 |
$342 |
D/D |
(723) |
208,653 |
|
- |
|
| Macrae Sandy |
PRESIDENT, CEO AND DIRECTOR |
• • – |
2025-04-22 |
4 |
D |
$0.78 |
$98,551 |
D/D |
(126,950) |
2,325,898 |
|
- |
|
| Dubois-Stringfellow Nathalie |
SVP-CHIEF DEVELOPMENT OFFICER |
• – – |
2025-04-22 |
4 |
D |
$0.78 |
$24,738 |
D/D |
(31,866) |
801,539 |
|
- |
|
| Duraibabu Prathyusha |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2025-04-22 |
4 |
D |
$0.78 |
$24,738 |
D/D |
(31,866) |
779,937 |
|
- |
|
| Willoughby Scott B. |
SVP, GEN. COUNSEL & SECRETARY |
• – – |
2025-04-22 |
4 |
D |
$0.78 |
$24,738 |
D/D |
(31,866) |
782,976 |
|
- |
|
| Davis Gregory D |
Head of Research & Technology |
• – – |
2025-04-22 |
4 |
D |
$0.78 |
$5,207 |
D/D |
(6,708) |
209,376 |
|
- |
|
| Duraibabu Prathyusha |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
811,803 |
|
- |
|
| Duraibabu Prathyusha |
SVP, CHIEF FINANCIAL OFFICER |
• – – |
2025-02-25 |
4 |
D |
$0.96 |
$1,315 |
D/D |
(1,375) |
691,803 |
|
- |
|
| Willoughby Scott B. |
SVP, GEN. COUNSEL & SECRETARY |
• – – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
814,842 |
|
- |
|
| Willoughby Scott B. |
SVP, GEN. COUNSEL & SECRETARY |
• – – |
2025-02-25 |
4 |
D |
$0.96 |
$1,315 |
D/D |
(1,375) |
694,842 |
|
- |
|
| Davis Gregory D |
Head of Research & Technology |
• – – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
49,726 |
216,084 |
|
- |
|
| Davis Gregory D |
Head of Research & Technology |
• – – |
2025-02-25 |
4 |
D |
$0.96 |
$485 |
D/D |
(507) |
166,358 |
|
- |
|
| Macrae Sandy |
PRESIDENT, CEO AND DIRECTOR |
• • – |
2025-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
375,000 |
2,452,848 |
|
- |
|
435 Records found
|
|
Page 1 of 18 |
|
|
0.04 (6.83%) 
